Sangamo Therapeutics
Richmond, California, United States · Biotechnology, Genetics, Health Care
Sangamo Therapeutics, Inc. is a genomic medicine company based in California.
Key facts
- Headquarters
- Richmond, California, United States
- Employees
- 321
- Industries
- Biotechnology, Genetics, Health Care
- Website
- www.sangamo.com
- Company page
Recent activity at Sangamo Therapeutics
- : SEC 8-K (7.01):
- : SEC 8-K (2.01): On September 17, 2026, Sangamo Therapeutics, Inc. completed the sale of its assets primarily related to the AAV gene therapy product candidate for Fabry disease, ST-920, to PTC Therapeutics, Inc. This transaction, finalized under Chapter 11 bankruptcy proceedings, involves total consideration of $111 million in cash at closing, plus up to $100 million in contingent consideration based on specified milestones. The Asset Purchase Agreement was dated August 25, 2026, and the sale was authorized by a Sale Order from the U.S. Bankruptcy Court. The completion of this sale marks a significant step for the Company as it continues operating under a debtor-in-possession status. The strategic implications include monetary relief for the company's liabilities amidst ongoing Chapter 11 proceedings.
- : SEC 8-K (2.01):
- : SEC 8-K (1.01): On August 25, 2026, Sangamo Therapeutics, Inc. entered into an Asset Purchase Agreement with PTC Therapeutics, Inc. under which Sangamo agreed to sell its assets primarily related to ST-920, a gene therapy candidate for Fabry disease. The total consideration for the sale is $111,000,000 in cash at closing, along with contingent payments up to an additional $100,000,000 based on FDA milestones. The milestone payments include $80,000,000 upon accelerated FDA approval and $20,000,000 upon full approval of the biologics license application for ST-920. This transaction follows Sangamo's Chapter 11 bankruptcy filing and is part of their restructuring efforts to optimize their asset portfolio.
- : SEC 8-K (8.01):
- : SEC 8-K (7.01):
- : SEC 8-K (1.03):
- : SEC 8-K (8.01):
- : SEC 8-K (1.01): On June 23, 2026, Sangamo Therapeutics, Inc. filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code. The company is continuing operations as a 'debtor-in-possession' and has sought first-day motions for emergency relief and debtor-in-possession financing. Additionally, a Stalking Horse Asset Purchase Agreement was entered into on June 22, 2026, with Eli Lilly and Company, for the sale of the Company’s technology platforms, including the AAV capsid engineering platform and intellectual property rights. The objective of the bankruptcy case is to maximize value for stakeholders, potentially through the sale of all or substantially all assets.
- : Sangamo Therapeutics Secures Funding Through Underwritten Offering
Sangamo Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Feb 2026 | Post-IPO Equity | $16.5M |
Leadership
- Scott Willoughby, Chief Legal Officer
- Sandy Macrae, Chief Executive Officer
- Nikunj Jain, Principal Accounting Officer
Verified email and direct lines for Sangamo Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Sangamo Therapeutics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Sangamo Therapeutics in the news
- PTC Wins Sangamo's Fabry Gene Therapy in Bankruptcy Auction - CGTLive® (Aug 24, 2026)
- PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy - MedCity News (Aug 13, 2026)
- PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry market - Fierce Biotech (Aug 13, 2026)
- Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact - BioSpace (Jan 02, 2025)
- Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases - PR Newswire (Dec 19, 2024)
- Astellas pays Sangamo $20M upfront to improve neurological gene therapy capabilities - Fierce Biotech (Dec 19, 2024)
- Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases - Biogen (Feb 27, 2020)
- Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers - Fierce Biotech (Jun 23, 2026)
Companies similar to Sangamo Therapeutics
- Genethon · Biotechnology, Genetics, Health Care, Therapeutics
- Crispr Therapeutics · Biotechnology, Genetics, Health Care, Therapeutics
- Rocket Pharmaceuticals · Biotechnology, Genetics, Health Care, Therapeutics
- uniQure · Biotechnology, Genetics, Health Care, Therapeutics
- Prime Medicine · Biotechnology, Genetics, Health Care, Therapeutics
About Sangamo Therapeutics: questions and answers
What does Sangamo Therapeutics do?
Sangamo Therapeutics, Inc. is a genomic medicine company based in California.
Where is Sangamo Therapeutics headquartered?
Sangamo Therapeutics is headquartered in Richmond, California, United States.
How many employees does Sangamo Therapeutics have?
Sangamo Therapeutics has about 321 employees.
Has Sangamo Therapeutics raised funding?
Yes. Fundz has recorded 1 funding event for Sangamo Therapeutics. The most recent, Post-IPO Equity of $16.5M, was in Feb 2026.
Who leads Sangamo Therapeutics?
Sandy Macrae is a Chief Executive Officer at Sangamo Therapeutics.
What is the latest news on Sangamo Therapeutics?
On Oct 14, 2026, SEC 8-K (7.01):
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy